Journal: Journal of Pharmaceutical Analysis
Article Title: Hemodynamic disturbance and mTORC1 activation: Unveiling the biomechanical pathogenesis of thoracic aortic aneurysms in Marfan syndrome
doi: 10.1016/j.jpha.2024.101120
Figure Lengend Snippet: Rapamycin mitigates mechanistic target of rapamycin complex 1 (mTORC1) activation induced by oscillatory shear stress (OSS) in Fbn1 +/C1039G Mice. (A) Visualization of blood flow velocity and streamlines within the aortic lumen captures the dynamic hemodynamic alterations related to aneurysm progression and the disturbed flow of the three groups: wild-type (WT) littermates, Fbn1 +/C1039G mice, and Fbn1 +/C1039G mice subjected to long-term rapamycin treatment ( Fbn1 +/C1039G + RA). (B) The presence of OSS across the aortic regions of the three groups: WT littermates, Fbn1 +/C1039G mice, and Fbn1 +/C1039G + RA, with OSS areas marked in gray. (C) Comparative aortic velocity mapping and cross-sectional OSS distribution among the three groups, with OSS zones delineated by white dashed lines. (D) Immunohistochemical detection of phosphorylated S6 (p-S6) in ascending aortic sections from the three groups. (E) Enlarged view of the OSS regions from the respective groups. (F) Quantification of p-S6 fluorescence intensity across the groups, indicating the modulation of mTORC1 signaling by rapamycin. (G–I) Western blot analysis profiling the expression of phosphorylated S6 kinase (p-S6K), total S6 kinase (t-S6K), phosphorylated S6 (p-S6), total S6 (t-S6), and statistical evaluation of protein expressions at 12 (G), 20 (H), and 30 week (I). Data expressed as mean ± standard error of the mean (SEM) for n = 6 per group. One-way analysis of variance (ANOVA) was utilized to assess statistical significance, denoted by ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001; NS: not significant.
Article Snippet: Antibodies against phosphorylated ribosomal protein S6 kinase (p-S6K, Thr421/Ser 424, 9204), total S6K (t-S6K, 9202), p-S6 (Ser 235/236, 4858), t-S6 (2217), phosphorylated extracellular signal-regulated kinase ( p -ERK, 9101), and p -Smad 2 (18338) were purchased from Cell Signaling Technology (Boston, MA, USA).
Techniques: Activation Assay, Shear, Immunohistochemical staining, Fluorescence, Western Blot, Expressing